CPX Targeting DJ-1 Triggers ROS-induced Cell Death and Protective Autophagy in Colorectal Cancer

Rationale: Colorectal cancer (CRC) is one of the most common cancers worldwide. Ciclopirox olamine (CPX) has recently been identified to be a promising anticancer candidate; however, novel activities and detailed mechanisms remain to be uncovered. Methods: The cytotoxic potential of CPX towards CRC cells was examined in vitro and in vivo. The global gene expression pattern, ROS levels, mitochondrial function, autophagy, apoptosis, etc. were determined between control and CPX-treated CRC cells. Results: We found that CPX inhibited CRC growth by inhibiting proliferation and inducing apoptosis both in vitro and in vivo. The anti-cancer effects of CPX involved the downregulation of DJ-1, and overexpression of DJ-1 could reverse the cytotoxic effect of CPX on CRC cells. The loss of DJ-1 resulted in mitochondrial dysfunction and ROS accumulation, thus leading to CRC growth inhibition. The cytoprotective autophagy was provoked simultaneously, and blocking autophagy pharmacologically or genetically could further enhance the anti-cancer efficacy of CPX. Conclusion: Our study demonstrates that DJ-1 loss-induced ROS accumulation plays a pivotal role in CPX-mediated CRC inhibition, providing a further understanding for CRC treatment via modulating compensatory protective autophagy.

[1]  W. Jin Novel Insights into PARK7 (DJ-1), a Potential Anti-Cancer Therapeutic Target, and Implications for Cancer Progression , 2020, Journal of clinical medicine.

[2]  P. Leedman,et al.  Altered Iron Metabolism and Impact in Cancer Biology, Metastasis, and Immunology , 2020, Frontiers in Oncology.

[3]  Hao Zhou,et al.  Pathological Roles of Mitochondrial Oxidative Stress and Mitochondrial Dynamics in Cardiac Microvascular Ischemia/Reperfusion Injury , 2020, Biomolecules.

[4]  M. McKenna,et al.  Preclinical Pharmacokinetics of Fosciclopirox, a Novel Treatment of Urothelial Cancers, in Rats and Dogs , 2019, The Journal of Pharmacology and Experimental Therapeutics.

[5]  Yong‐Chul Kim,et al.  Ciclopirox inhibits Hepatitis B Virus secretion by blocking capsid assembly , 2019, Nature Communications.

[6]  Yitao Wang,et al.  DJ-1 promotes colorectal cancer progression through activating PLAGL2/Wnt/BMP4 axis , 2018, Cell Death & Disease.

[7]  L. Morrison,et al.  Antifungal drug ciclopirox olamine reduces HSV‐1 replication and disease in mice , 2018, Antiviral research.

[8]  Yuquan Wei,et al.  Identification of ANXA2 (annexin A2) as a specific bleomycin target to induce pulmonary fibrosis by impeding TFEB-mediated autophagic flux , 2018, Autophagy.

[9]  Michalis V. Karamouzis,et al.  Superior efficacy of the antifungal agent ciclopirox olamine over gemcitabine in pancreatic cancer models , 2017, Oncotarget.

[10]  M. Karamouzis,et al.  74PEffect of ciclopirox olamine in immunotherapy effect by stimulating immunogenic cell death in pancreatic cancer , 2017 .

[11]  Jie J. Zheng,et al.  Targeting Histone Demethylases in MYC-Driven Neuroblastomas with Ciclopirox. , 2017, Cancer research.

[12]  A. Jemal,et al.  Colorectal cancer statistics, 2017 , 2017, CA: a cancer journal for clinicians.

[13]  Y. Odaka,et al.  Ciclopirox inhibits cancer cell proliferation by suppression of Cdc25A , 2017, Genes & cancer.

[14]  P. Auberger,et al.  Autophagy, a key mechanism of oncogenesis and resistance in leukemia. , 2017, Blood.

[15]  Yuquan Wei,et al.  Antileukemia Effect of Ciclopirox Olamine Is Mediated by Downregulation of Intracellular Ferritin and Inhibition β-Catenin-c-Myc Signaling Pathway in Glucocorticoid Resistant T-ALL Cell Lines , 2016, PloS one.

[16]  T. Shen,et al.  Repositioning the Old Fungicide Ciclopirox for New Medical Uses. , 2016, Current pharmaceutical design.

[17]  Yuquan Wei,et al.  PRKAA/AMPK restricts HBV replication through promotion of autophagic degradation , 2016, Autophagy.

[18]  Debashis Sahoo,et al.  CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer. , 2016, The New England journal of medicine.

[19]  Sangeeta Khare,et al.  Guidelines for the use and interpretation of assays formonitoring autophagy (3rd edition) , 2016 .

[20]  J. Chan,et al.  Activation of endogenous antioxidants as a common therapeutic strategy against cancer, neurodegeneration and cardiovascular diseases: A lesson learnt from DJ-1. , 2015, Pharmacology & therapeutics.

[21]  A. Chaudhary,et al.  Targeting autophagy to overcome drug resistance in cancer therapy. , 2015, Future medicinal chemistry.

[22]  T. Mak,et al.  DJ-1 links muscle ROS production with metabolic reprogramming and systemic energy homeostasis in mice , 2015, Nature Communications.

[23]  Bo Yang,et al.  DJ-1 as a human oncogene and potential therapeutic target. , 2015, Biochemical pharmacology.

[24]  Yan Luo,et al.  Ciclopirox induces autophagy through reactive oxygen species-mediated activation of JNK signaling pathway , 2014, Oncotarget.

[25]  Jin-jian Lu,et al.  DJ-1 mediates the resistance of cancer cells to dihydroartemisinin through reactive oxygen species removal. , 2014, Free radical biology & medicine.

[26]  M. Minden,et al.  Oral ciclopirox olamine displays biological activity in a phase I study in patients with advanced hematologic malignancies , 2014, American journal of hematology.

[27]  D. Gewirtz The four faces of autophagy: implications for cancer therapy. , 2014, Cancer research.

[28]  M. Mathews,et al.  Blocking eIF5A modification in cervical cancer cells alters the expression of cancer-related genes and suppresses cell proliferation. , 2014, Cancer research.

[29]  T. Mak,et al.  Modulation of oxidative stress as an anticancer strategy , 2013, Nature Reviews Drug Discovery.

[30]  Z. Huang,et al.  Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment , 2013, Cell Death and Disease.

[31]  P. Agostinis,et al.  Autophagy: shaping the tumor microenvironment and therapeutic response. , 2013, Trends in molecular medicine.

[32]  T. J. Cook,et al.  DJ-1 isoforms in whole blood as potential biomarkers of Parkinson disease , 2012, Scientific Reports.

[33]  Robert Clarke,et al.  Guidelines for the use and interpretation of assays for monitoring autophagy , 2012 .

[34]  R. Kurzrock,et al.  Autophagy as a target for anticancer therapy , 2011, Nature Reviews Clinical Oncology.

[35]  Shengbing Huang,et al.  The Role of Autophagy in Cancer: Therapeutic Implications , 2011, Molecular Cancer Therapeutics.

[36]  William A Weiss,et al.  Principles and Current Strategies for Targeting Autophagy for Cancer Treatment , 2011, Clinical Cancer Research.

[37]  M. Lotze,et al.  HMGB1-induced autophagy promotes chemotherapy resistance in leukemia cells , 2011, Leukemia.

[38]  David W. Miller,et al.  DJ-1 acts in parallel to the PINK1/parkin pathway to control mitochondrial function and autophagy. , 2011, Human molecular genetics.

[39]  Xiuzhen Han,et al.  The antitumor activity of the fungicide ciclopirox , 2010, International journal of cancer.

[40]  D. Monti,et al.  Ciclopirox: recent nonclinical and clinical data relevant to its use as a topical antimycotic agent. , 2010, Drugs.

[41]  David S. Park,et al.  Loss of the Parkinson's disease-linked gene DJ-1 perturbs mitochondrial dynamics. , 2010, Human molecular genetics.

[42]  J. Im,et al.  DJ-1 protects against oxidative damage by regulating the thioredoxin/ASK1 complex , 2010, Neuroscience Research.

[43]  D. Sargent,et al.  Adjuvant chemotherapy for resected stage II and III colon cancer: comparison of two widely used prognostic calculators. , 2010, Seminars in oncology.

[44]  J. Dick,et al.  Chelation of intracellular iron with the antifungal agent ciclopirox olamine induces cell death in leukemia and myeloma cells. , 2009, Blood.

[45]  Peng Huang,et al.  Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? , 2009, Nature Reviews Drug Discovery.

[46]  Deepti Malhotra,et al.  Decline in Nrf2-regulated Antioxidants in Chronic Obstructive Pulmonary Disease Lungs Due to Loss of Its Positive Regulator, Dj-1 , 2022 .

[47]  V. A. Flørenes,et al.  Expression and clinical role of DJ-1, a negative regulator of PTEN, in ovarian carcinoma. , 2008, Human pathology.

[48]  T. Mak,et al.  DJ-1, a cancer- and Parkinson's disease-associated protein, stabilizes the antioxidant transcriptional master regulator Nrf2 , 2006, Proceedings of the National Academy of Sciences.

[49]  Y. Kondo,et al.  Autophagy and Cancer Therapy , 2006, Autophagy.

[50]  Wenbo Zhou,et al.  DJ-1 Up-regulates Glutathione Synthesis during Oxidative Stress and Inhibits A53T α-Synuclein Toxicity* , 2005, Journal of Biological Chemistry.

[51]  Raymond Sawaya,et al.  The role of autophagy in cancer development and response to therapy , 2005, Nature Reviews Cancer.

[52]  Xin Zhao,et al.  Interaction of DJ-1 with Daxx inhibits apoptosis signal-regulating kinase 1 activity and cell death. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[53]  T. Mak,et al.  DJ-1, a novel regulator of the tumor suppressor PTEN. , 2005, Cancer cell.

[54]  D. Jäger,et al.  [Systemic therapy for colorectal cancer]. , 2005, Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen.

[55]  R. Krüger,et al.  Novel homozygous p.E64D mutation in DJ1 in early onset Parkinson disease (PARK7) , 2004, Human mutation.

[56]  Y. Hod Differential control of apoptosis by DJ‐1 in prostate benign and cancer cells , 2004, Journal of cellular biochemistry.

[57]  M. Schaller,et al.  Ciclopirox Olamine Treatment Affects the Expression Pattern of Candida albicans Genes Encoding Virulence Factors, Iron Metabolism Proteins, and Drug Resistance Factors , 2003, Antimicrobial Agents and Chemotherapy.

[58]  R. Wenger,et al.  The antimycotic ciclopirox olamine induces HIF‐1α stability, VEGF expression, and angiogenesis , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[59]  Patrizia Rizzu,et al.  Mutations in the DJ-1 Gene Associated with Autosomal Recessive Early-Onset Parkinsonism , 2002, Science.

[60]  H. Kleinman,et al.  The antifungal drug ciclopirox inhibits deoxyhypusine and proline hydroxylation, endothelial cell growth and angiogenesis in vitro , 2002, International journal of cancer.

[61]  Kohei Miyazono,et al.  Mammalian thioredoxin is a direct inhibitor of apoptosis signal‐regulating kinase (ASK) 1 , 1998, The EMBO journal.

[62]  H. Korting,et al.  The hydroxypyridones: a class of antimycotics of its own , 1997, Mycoses.

[63]  J. Hardcastle,et al.  Colorectal cancer , 1993, Europe Against Cancer European Commission Series for General Practitioners.

[64]  R. N. Brogden,et al.  Ciclopirox olamine 1% cream. A preliminary review of its antimicrobial activity and therapeutic use. , 1985, Drugs.

[65]  E. Schütz,et al.  [Studies on the pharmacology and toxicology of ciclopiroxolamine (author's transl)]. , 1981, Arzneimittel-Forschung.

[66]  H. Eckert,et al.  [Pharmacokinetics and biotransformation of the antimycotic drug ciclopiroxolamine in animals and man after topical and systemic administration]. , 1981, Arzneimittel-Forschung.

[67]  HighWire Press,et al.  The journal of pharmacology and experimental therapeutics , 1909 .